Pharma companies must factor tough standing requirements into IPR strategies

Pharma companies must factor tough standing requirements into IPR strategies

SCOTUS petition denial in Argentum v Novartis highlights the difficult choices facing those who wish to challenge patents at the PTAB

Unlock unlimited access to all IAM content